SRPK2 and familial pancreatic carcinoma: SRPK2 expression was closely associated with multiple aggressive clinicopathologic characteristics of CRC patients, including tumor differentiation, T stage, lymph node metastasis and UICC stage, which was consistent with our previous study in pancreatic cancer [15], showing that SRPK2 expression was positively associated with tumor T stage and UICC stage.